The field of antibody production has witnessed significant technological advancements over the past years, particularly in hybridoma technology, which remains a cornerstone for monoclonal antibody (mAb) production.
Electrofusion Technology in Hybridoma Preparation
Electrofusion technology can be applied as a cell engineering technique for hybridoma preparation. This method offers substantial improvements in efficiency and control over traditional polyethylene glycol-mediated cell fusion. Electrofusion involves electric field intensity, number of pulses, and pulse duration. However, key challenges in adopting electrofusion include selecting appropriate instruments, optimizing electrical parameters, and precisely controlling cell conditions. Despite this, electrofusion represents a promising advancement for enhancing the specificity and yield of monoclonal antibodies.1
Hybridoma Cell Screening and Expansion
The process of generating monoclonal antibodies through hybridoma technology involves screening hybridoma cells to select those producing the desired antibodies. This is typically achieved using enzyme-linked immunosorbent assay (ELISA) techniques, among others, to identify antibodies with the right specificity. Following screening, hybridomas that produce the desired antibodies are cloned and propagated to obtain stable cell populations for large-scale antibody production. This expansion can be performed either in vitro, using tissue culture techniques, or in vivo, by inoculating hybridoma cells into the abdomen of a mouse. However, the technology is not without limitations, such as long production times, resource-intensive processes, susceptibility to contamination, and challenges in generating short peptides and fragment antigens.
Clinical Significance and Applications
Hybridoma technology's clinical significance is vast, providing monoclonal antibodies for various diagnostic tests, cancer treatments, and research applications. The specificity and reliability of monoclonal antibodies produced via hybridoma technology have made it an indispensable tool in the diagnosis and treatment of numerous diseases. This technology enables the production of antibodies for detecting foreign antigens, identifying different strains of pathogens, and even treating viral diseases such as AIDS. Moreover, monoclonal antibodies are instrumental in radioimmunodetection and radioimmunotherapy of cancer, highlighting their critical role in modern medicine.2 Biointron offers hybridoma sequencing services for antibody discovery and production.
Kou, J., Shen, J., Wang, Z., & Yu, W. (2023). Advances in hybridoma preparation using electrofusion technology. Biotechnology Journal, 18(10), 2200428. https://doi.org/10.1002/biot.202200428
Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering and Biotechnology, 19(1), 1-12. https://doi.org/10.1186/s43141-021-00264-6
The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.
Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.
Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.
Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.